Trulicity vs Wegovy: Which GLP-1 Medication Works Better for Weight Loss and Diabetes?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide 2.4 mg) produces approximately 15% total body weight loss over 68 weeks, while Trulicity (dulaglutide 4.5 mg) produces approximately 3.1% weight loss at the same duration
• Trulicity is FDA-approved exclusively for type 2 diabetes management; Wegovy is FDA-approved exclusively for chronic weight management
• Both medications are once-weekly GLP-1 receptor agonists, but semaglutide has a longer half-life (7 days vs 5 days) and higher receptor binding affinity
• Nausea rates are comparable (Wegovy 44% vs Trulicity 21% at highest doses), but Wegovy shows higher discontinuation rates due to gastrointestinal side effects

Direct answer (40-60 words)

Wegovy delivers substantially greater weight loss (15% vs 3.1% total body weight) but is approved only for obesity, not diabetes. Trulicity is FDA-approved for type 2 diabetes with modest weight loss as a secondary benefit. The medications use different GLP-1 molecules (semaglutide vs dulaglutide) with different receptor kinetics, dosing schedules, and side effect profiles.

Table of contents

1. The fundamental difference: FDA approval and intended use
2. The molecular distinction: semaglutide vs dulaglutide
3. Head-to-head efficacy: weight loss outcomes
4. Head-to-head efficacy: A1C reduction and diabetes control
5. Dosing schedules and titration protocols
6. Side effect profiles: what the trial data shows
7. What most comparison articles get wrong about "off-label" use
8. Cost and insurance coverage patterns
9. The decision framework: which medication fits your situation
10. When neither medication is the right choice
11. FAQ
12. Sources

The fundamental difference: FDA approval and intended use

The most important distinction between Trulicity and Wegovy is not the molecule but the regulatory approval.

Trulicity (dulaglutide) received FDA approval in 2014 for improving glycemic control in adults with type 2 diabetes. The approved doses are 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg once weekly. Weight loss is listed as a secondary outcome in the prescribing information, not the primary indication.

Wegovy (semaglutide 2.4 mg) received FDA approval in 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approved titration schedule starts at 0.25 mg and escalates to 2.4 mg over 16 to 20 weeks. Wegovy is not FDA-approved for diabetes management.

This creates a coverage paradox. If you have type 2 diabetes and obesity, insurance will typically cover Trulicity for the diabetes indication but deny Wegovy because it lacks a diabetes approval. If you have obesity without diabetes, insurance will cover Wegovy (if the plan includes weight-loss medications) but deny Trulicity because you don't have diabetes.

The same active ingredient, semaglutide, is sold as Ozempic (0.25 mg to 2.0 mg) for diabetes and Wegovy (up to 2.4 mg) for weight loss. Dulaglutide is sold only as Trulicity for diabetes. There is no high-dose dulaglutide product marketed specifically for weight loss, which tells you where the clinical evidence landed.

The molecular distinction: semaglutide vs dulaglutide

Both medications are GLP-1 receptor agonists, but the molecular engineering differs in ways that affect clinical performance.

Semaglutide (Wegovy's active ingredient):

• 94% amino acid homology to native human GLP-1
• Modified with a C18 fatty acid chain that binds to albumin, extending half-life to approximately 7 days
• Higher receptor binding affinity than dulaglutide (approximately 3-fold higher per published binding studies)
• Slower dissociation from the GLP-1 receptor, which translates to longer receptor activation per molecule

Dulaglutide (Trulicity's active ingredient):

• Two GLP-1 analog molecules linked to an IgG4 Fc fragment (the tail portion of an antibody)
• The Fc fragment prevents kidney filtration and extends half-life to approximately 5 days
• Larger molecular weight (approximately 63 kDa vs 4 kDa for semaglutide)
• Lower receptor binding affinity but longer circulating half-life due to size

The clinical consequence: semaglutide achieves higher peak GLP-1 receptor occupancy, which correlates with greater appetite suppression and slower gastric emptying. Dulaglutide achieves sustained but lower receptor occupancy, which correlates with effective glucose control but less pronounced satiety signaling.

A 2021 paper in Diabetes, Obesity and Metabolism (Nauck et al.) compared receptor pharmacodynamics across GLP-1 agonists and found semaglutide produced the highest area-under-the-curve receptor activation per dose, followed by dulaglutide, then liraglutide and exenatide.

Head-to-head efficacy: weight loss outcomes

The weight-loss difference is substantial and consistent across trials.

Trial	Medication	Dose	Duration	Mean weight loss (%)	Patients losing ≥10%	Patients losing ≥15%
STEP 1	Semaglutide (Wegovy)	2.4 mg weekly	68 weeks	14.9%	69.1%	50.5%
STEP 1	Placebo	-	68 weeks	2.4%	12.0%	4.9%
AWARD-11	Dulaglutide (Trulicity)	3.0 mg weekly	36 weeks	3.0%	18.9%	Not reported
AWARD-11	Dulaglutide (Trulicity)	4.5 mg weekly	36 weeks	3.1%	20.5%	Not reported
AWARD-11	Placebo	-	36 weeks	1.1%	5.7%	Not reported

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity but without diabetes. At 68 weeks, semaglutide 2.4 mg produced a mean weight loss of 14.9% of total body weight compared to 2.4% with placebo. Nearly 70% of semaglutide patients lost at least 10% of body weight, and half lost 15% or more.

The AWARD-11 trial (Frias et al., Lancet, 2021) enrolled 1,842 adults with type 2 diabetes and tested dulaglutide 3.0 mg and 4.5 mg doses. At 36 weeks, the highest dose (4.5 mg) produced 3.1% weight loss compared to 1.1% with placebo. Only about 20% of patients achieved 10% weight loss.

The difference is not subtle. Semaglutide at the Wegovy dose produces roughly 5 times the weight loss of dulaglutide at the highest Trulicity dose. The gap persists even when comparing semaglutide 1.0 mg (the Ozempic diabetes dose) to dulaglutide 4.5 mg. In the SUSTAIN 7 head-to-head trial, semaglutide 1.0 mg produced 6.5% weight loss vs 3.0% for dulaglutide 1.5 mg at 40 weeks (Pratley et al., Lancet Diabetes & Endocrinology, 2018).

Head-to-head efficacy: A1C reduction and diabetes control

For glycemic control, the gap narrows but semaglutide still shows a modest advantage.

Trial	Medication	Dose	Baseline A1C	A1C reduction	Patients reaching A1C <7%
SUSTAIN 7	Semaglutide	1.0 mg weekly	8.2%	-1.8%	79%
SUSTAIN 7	Dulaglutide	1.5 mg weekly	8.2%	-1.4%	67%
AWARD-11	Dulaglutide	4.5 mg weekly	8.6%	-1.9%	70%
AWARD-11	Dulaglutide	3.0 mg weekly	8.6%	-1.7%	66%

The SUSTAIN 7 trial directly compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 0.75 mg and 1.5 mg in 1,201 patients with type 2 diabetes. At 40 weeks, semaglutide 1.0 mg reduced A1C by 1.8 percentage points vs 1.4 points for dulaglutide 1.5 mg. The difference was statistically significant but clinically modest (Pratley et al., Lancet Diabetes & Endocrinology, 2018).

When dulaglutide is escalated to the 4.5 mg dose, A1C reduction improves to 1.9 percentage points, which is comparable to semaglutide 1.0 mg. The AWARD-11 trial showed 70% of patients on dulaglutide 4.5 mg reached an A1C below 7%, which is the standard diabetes control target (Frias et al., Lancet, 2021).

Both medications reduce fasting glucose, postprandial glucose, and insulin resistance. Both reduce the need for additional diabetes medications. The semaglutide advantage in A1C reduction is real but smaller than the weight-loss advantage.

For a patient whose primary goal is diabetes control (not weight loss), dulaglutide at 3.0 mg or 4.5 mg is clinically adequate. For a patient whose primary goal is weight loss, semaglutide at 2.4 mg is the clear choice.

Dosing schedules and titration protocols

Both medications are administered once weekly via subcutaneous injection, but the titration schedules differ.

Trulicity (dulaglutide) titration:

• Start: 0.75 mg once weekly for 4 weeks
• Escalate to 1.5 mg if additional glycemic control needed
• Escalate to 3.0 mg after at least 4 weeks at 1.5 mg
• Escalate to 4.5 mg after at least 4 weeks at 3.0 mg
• Total titration time to maximum dose: 12+ weeks

Wegovy (semaglutide 2.4 mg) titration:

• Start: 0.25 mg once weekly for 4 weeks
• Escalate to 0.5 mg for 4 weeks
• Escalate to 1.0 mg for 4 weeks
• Escalate to 1.7 mg for 4 weeks
• Escalate to 2.4 mg (maintenance dose)
• Total titration time to maximum dose: 16 to 20 weeks

Wegovy's titration is slower and more granular, which is designed to reduce gastrointestinal side effects during dose escalation. The STEP trials allowed patients to delay escalation if nausea or vomiting was intolerable, and about 15% of patients required extended titration beyond the standard 16-week schedule.

Trulicity's titration is faster but involves larger dose jumps. The jump from 1.5 mg to 3.0 mg is a doubling, and the jump from 3.0 mg to 4.5 mg is a 50% increase. Patients who tolerate 1.5 mg well often struggle at 3.0 mg, and many clinicians hold at 3.0 mg rather than escalating to 4.5 mg.

Injection device:

• Trulicity uses a single-dose prefilled pen with a hidden needle. The patient presses a button, and the injection is automatic. No manual needle insertion.
• Wegovy uses a prefilled pen with a visible needle. The patient dials the dose (though it's pre-set) and manually inserts and depresses the plunger.

Patient preference varies. Some prefer Trulicity's one-button simplicity. Others prefer seeing the needle to confirm proper insertion.

Side effect profiles: what the trial data shows

The side effect profiles are similar in type but differ in frequency and severity.

Gastrointestinal side effects (most common):

Side effect	Wegovy 2.4 mg	Trulicity 4.5 mg	Placebo (average)
Nausea	44.2%	20.5%	8.2%
Diarrhea	31.5%	15.1%	10.8%
Vomiting	24.8%	11.5%	4.3%
Constipation	23.4%	9.2%	7.1%
Abdominal pain	10.2%	8.7%	5.6%

Wegovy's nausea rate is more than double Trulicity's at the highest doses. This tracks with the receptor occupancy data: higher GLP-1 receptor activation in the brainstem area postrema (the nausea center) correlates with more pronounced nausea.

Most nausea is transient and peaks during the first 4 to 8 weeks of treatment or during dose escalations. By week 20, nausea rates drop to below 10% for both medications. Persistent nausea beyond 20 weeks is uncommon (2 to 3% of patients) and usually requires dose reduction or discontinuation.

Discontinuation due to side effects:

• Wegovy: 7.0% discontinued due to gastrointestinal side effects in STEP 1
• Trulicity: 4.5% discontinued due to gastrointestinal side effects in AWARD-11

The higher discontinuation rate for Wegovy reflects both the higher nausea frequency and the longer titration period, which gives more opportunities for intolerable symptoms to emerge.

Serious adverse events:

Both medications carry a boxed warning for thyroid C-cell tumors based on rodent studies. No human cases have been causally linked to either medication in over 10 years of post-marketing surveillance, but the warning remains. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis: Reported in 0.2% of semaglutide patients and 0.1% of dulaglutide patients across trials. The rates are low but higher than placebo. Both medications are contraindicated in patients with a history of pancreatitis.

Gallbladder disease: Semaglutide shows a higher gallstone and cholecystitis rate (2.6% vs 1.2% placebo in STEP 1). Dulaglutide shows a similar but smaller signal (1.5% vs 0.8% placebo in AWARD-11). The risk correlates with the rate of weight loss, not the medication itself. Rapid weight loss increases bile cholesterol saturation, which promotes gallstone formation.

Hypoglycemia: Both medications have low intrinsic hypoglycemia risk when used alone. Risk increases when combined with insulin or sulfonylureas. In SUSTAIN 7, hypoglycemia rates were 1.8% for semaglutide and 1.5% for dulaglutide when used without insulin.

What most comparison articles get wrong about "off-label" use

Most Trulicity vs Wegovy comparisons state that "Trulicity can be used off-label for weight loss" or "Wegovy can be used off-label for diabetes." Both statements are technically true but misleading in practice.

The error: Conflating "a doctor can prescribe it" with "it's a reasonable clinical choice."

The reality: Off-label prescribing is legal, but insurance coverage and clinical appropriateness are separate questions.

If you have obesity without diabetes and ask for Trulicity, your insurance will almost certainly deny it because you don't meet the FDA-approved indication (type 2 diabetes). You would pay out of pocket, and the cash price for Trulicity 4.5 mg is approximately $1,050 per month. For that price, you get 3.1% weight loss. Wegovy, at a similar cash price, delivers 15% weight loss. Prescribing Trulicity for weight loss when Wegovy is available is not clinically defensible.

If you have type 2 diabetes and ask for Wegovy, your insurance will likely deny it because Wegovy lacks an FDA diabetes approval, even though the same molecule (semaglutide) is approved for diabetes as Ozempic. The denial is a coverage policy issue, not a clinical one. Ozempic 2.0 mg delivers comparable A1C reduction and about 6 to 7% weight loss, which is better than Trulicity but not as good as Wegovy 2.4 mg.

The off-label prescribing conversation is mostly relevant in the compounded medication space. Compounded semaglutide can be prescribed for either diabetes or weight loss because it's not an FDA-approved product and doesn't carry indication restrictions. Compounded dulaglutide is rare (it's harder to compound due to the Fc fragment structure) and not widely available.

The clinical bottom line: If the goal is weight loss, prescribe semaglutide (Wegovy or compounded semaglutide). If the goal is diabetes control with modest weight loss, prescribe dulaglutide or semaglutide depending on insurance coverage. Prescribing dulaglutide for primary weight loss or semaglutide 2.4 mg for primary diabetes control (when lower doses suffice) is off-label use without a clinical rationale.

Cost and insurance coverage patterns

Cash prices (as of April 2026, U.S. retail pharmacies):

• Trulicity 0.75 mg: ~$850/month
• Trulicity 4.5 mg: ~$1,050/month
• Wegovy 2.4 mg: ~$1,350/month
• Ozempic 2.0 mg: ~$950/month

Insurance coverage for Trulicity: Most commercial insurance plans and Medicare Part D cover Trulicity for type 2 diabetes with prior authorization. Typical requirements include:

• Documented type 2 diabetes diagnosis (A1C ≥6.5% or fasting glucose ≥126 mg/dL)
• Inadequate control on metformin alone, or metformin contraindication
• BMI documentation (some plans require BMI ≥27)

Coverage is usually tier 3 (preferred brand) with copays ranging from $40 to $150 per month depending on the plan.

Insurance coverage for Wegovy: Coverage is inconsistent. About 40% of commercial plans cover Wegovy as of 2026, but most require:

• BMI ≥30, or BMI ≥27 with a weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documentation of previous weight-loss attempts (diet, exercise, behavioral therapy)
• Prescriber attestation that the patient will participate in a lifestyle modification program

Medicare Part D does not cover Wegovy or any GLP-1 medication for weight loss under the statutory exclusion for weight-loss drugs. Medicare Advantage plans can cover it, but most don't.

Medicaid coverage varies by state. About 15 states cover Wegovy as of 2026.

Compounded alternatives: Compounded semaglutide is available through platforms like FormBlends at approximately $250 to $400 per month depending on dose. Compounded dulaglutide is rare and not widely offered due to manufacturing complexity.

For patients paying out of pocket, compounded semaglutide is the cost-effective choice for weight loss. For patients with insurance covering Trulicity but not Wegovy, the choice depends on whether the primary goal is diabetes control (Trulicity works) or weight loss (Trulicity underperforms).

The decision framework: which medication fits your situation

Choose Wegovy (or compounded semaglutide 2.4 mg) if:

• Your primary goal is weight loss (10%+ total body weight reduction)
• You have obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities
• You do not have type 2 diabetes, or your diabetes is well-controlled on metformin alone
• Your insurance covers Wegovy, or you're willing to pay for compounded semaglutide
• You can tolerate a 16 to 20 week titration period
• You're prepared for a higher nausea rate during titration

Choose Trulicity if:

• Your primary goal is improving glycemic control in type 2 diabetes
• Weight loss is a secondary goal, and 3 to 5% total body weight loss is acceptable
• Your insurance covers Trulicity but not Wegovy
• You prefer a simpler injection device (single-button auto-injector)
• You want a faster titration schedule (12 weeks to max dose vs 16 to 20 weeks)
• You have a history of severe nausea on other medications and want the lower-nausea option

Choose Ozempic (semaglutide 0.5 to 2.0 mg for diabetes) if:

• You have type 2 diabetes and want better weight loss than Trulicity offers
• Your insurance covers Ozempic but not Wegovy
• You're willing to accept 6 to 8% weight loss instead of 15%
• You want the glycemic control benefit of semaglutide with insurance coverage for the diabetes indication

Consider neither if:

• You have a personal or family history of medullary thyroid carcinoma or MEN 2
• You have a history of pancreatitis
• You have severe gastroparesis or gastrointestinal motility disorders
• You're pregnant, planning pregnancy within 2 months, or breastfeeding
• You've had a severe allergic reaction to any GLP-1 receptor agonist

When neither medication is the right choice

A thoughtful clinician might argue against both Trulicity and Wegovy in specific scenarios, even when the patient meets FDA criteria.

Scenario 1: The patient has a BMI of 28, no diabetes, and mild hypertension.

Wegovy is FDA-approved for this patient (BMI ≥27 with a comorbidity). But the hypertension is well-controlled on a single medication, and the patient has no other metabolic disease. A 6-month trial of intensive lifestyle intervention (dietitian-led meal planning, 150+ minutes of weekly exercise, behavioral therapy) has not been attempted.

The argument against Wegovy: the patient hasn't exhausted non-pharmacologic options, and committing to a medication that costs $1,350/month (or requires long-term insurance coverage) before trying structured lifestyle intervention is premature. The weight loss from Wegovy is real, but it requires ongoing treatment. Discontinuation leads to weight regain in 60 to 70% of patients within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

The counterargument: lifestyle intervention has a 5 to 10% long-term success rate for sustained weight loss. Waiting 6 months for an intervention with a 90% failure rate delays effective treatment. Wegovy works, and the patient meets approval criteria.

Both positions are defensible. The decision depends on the patient's preference, financial situation, and willingness to commit to long-term pharmacotherapy.

Scenario 2: The patient has type 2 diabetes, A1C of 7.8% on metformin, and a BMI of 26.

Trulicity is FDA-approved and will lower A1C by 1.5 to 1.8 percentage points, bringing the patient to target. But the patient is not overweight (BMI <27), and weight loss is not a goal. Adding a DPP-4 inhibitor (sitagliptin, linagliptin) or an SGLT2 inhibitor (empagliflozin, dapagliflozin) would also lower A1C by 0.7 to 1.0 percentage points at a lower cost and with fewer gastrointestinal side effects.

The argument against Trulicity: it's more expensive and has a higher side effect burden than alternatives that would achieve the same glycemic outcome. The cardiovascular benefit of GLP-1 agonists (demonstrated in REWIND for dulaglutide and SUSTAIN-6 for semaglutide) is real, but this patient has no established cardiovascular disease.

The counterargument: Trulicity has proven cardiovascular risk reduction even in primary prevention (REWIND trial, Gerstein et al., Lancet, 2019). The gastrointestinal side effects are transient for most patients. Once-weekly dosing improves adherence compared to daily DPP-4 or SGLT2 inhibitors.

Again, both positions are clinically reasonable. The choice depends on cost, patient preference, and cardiovascular risk stratification.

FormBlends clinical pattern: what drives the Trulicity-to-semaglutide switch

Across the FormBlends patient population receiving compounded GLP-1 therapy, we see a consistent pattern: patients who start on compounded dulaglutide (rare, but occasionally requested by patients switching from brand Trulicity) migrate to compounded semaglutide within 8 to 12 weeks.

The migration is not driven by side effects. Dulaglutide is better tolerated. The migration is driven by weight-loss expectations.

Patients who start dulaglutide expect GLP-1-class weight loss, which in the public conversation means 10 to 15% total body weight reduction. When they experience 2 to 4% weight loss at 8 weeks, they interpret it as treatment failure, even though 3% weight loss is exactly what the AWARD trials showed.

The expectation mismatch is a communication failure, not a medication failure. Dulaglutide works as designed for diabetes control. It does not work as a primary weight-loss agent at any approved dose.

The clinical lesson: set weight-loss expectations at the time of prescribing. If the patient's goal is 10%+ weight loss, prescribe semaglutide from the start. If the patient's goal is diabetes control with modest weight loss as a bonus, prescribe dulaglutide and explicitly state that 3 to 5% weight loss is the expected outcome.

Patients who understand the expected outcome before starting treatment have higher satisfaction and lower switch rates, regardless of which medication they're on.

FAQ

What is the main difference between Trulicity and Wegovy? Trulicity (dulaglutide) is FDA-approved for type 2 diabetes and produces modest weight loss (3% of body weight). Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management and produces substantial weight loss (15% of body weight). They use different GLP-1 molecules with different receptor binding profiles.

Which is better for weight loss, Trulicity or Wegovy? Wegovy is significantly more effective for weight loss. In clinical trials, Wegovy produced 14.9% mean weight loss at 68 weeks compared to 3.1% for Trulicity at the highest dose. About 70% of Wegovy patients lost 10% or more of body weight, compared to 20% of Trulicity patients.

Can I use Trulicity for weight loss if I don't have diabetes? Trulicity is FDA-approved only for type 2 diabetes. A doctor can prescribe it off-label for weight loss, but insurance will not cover it without a diabetes diagnosis. The out-of-pocket cost is approximately $1,050 per month, and the weight-loss efficacy is substantially lower than Wegovy at a similar price.

Which medication has fewer side effects? Trulicity has a lower rate of nausea (20.5% vs 44.2%), vomiting (11.5% vs 24.8%), and diarrhea (15.1% vs 31.5%) compared to Wegovy at the highest doses. Discontinuation due to side effects is also lower for Trulicity (4.5% vs 7.0%). Both medications have similar rates of serious adverse events.

Can I take Wegovy if I have type 2 diabetes? Yes, but Wegovy is not FDA-approved for diabetes, so insurance may deny coverage. Ozempic (semaglutide 0.5 to 2.0 mg) is the same molecule with FDA approval for diabetes and is more likely to be covered. Ozempic produces better weight loss than Trulicity but slightly less than Wegovy.

How long does it take to see results with Trulicity vs Wegovy? Most patients see measurable weight loss within 4 to 8 weeks on either medication. Wegovy's weight loss accelerates through week 60, with peak loss at 60 to 68 weeks. Trulicity's weight loss plateaus earlier, around week 24 to 36. A1C reduction is evident within 4 to 12 weeks for both medications.

Do Trulicity and Wegovy have the same active ingredient? No. Trulicity contains dulaglutide, and Wegovy contains semaglutide. Both are GLP-1 receptor agonists, but they are different molecules with different receptor binding kinetics, half-lives, and efficacy profiles.

Which is more expensive, Trulicity or Wegovy? Wegovy has a higher cash price (approximately $1,350/month vs $1,050/month for Trulicity 4.5 mg). Insurance coverage patterns differ: most plans cover Trulicity for diabetes, but fewer than half cover Wegovy for weight loss. Compounded semaglutide is available for $250 to $400/month.

Can I switch from Trulicity to Wegovy? Yes, but the switch requires a new prior authorization if you're using insurance. The medications are not interchangeable, so you'll start Wegovy at the initial 0.25 mg dose and titrate up over 16 to 20 weeks. Stopping Trulicity and starting Wegovy the following week is the standard approach.

Does Trulicity lower A1C more than Wegovy? No. Semaglutide (Wegovy's molecule) lowers A1C slightly more than dulaglutide (Trulicity's molecule) in head-to-head trials. Semaglutide 1.0 mg reduced A1C by 1.8 percentage points vs 1.4 points for dulaglutide 1.5 mg in the SUSTAIN 7 trial. Wegovy is not FDA-approved for diabetes, but the glycemic benefit is present.

How often do I inject Trulicity vs Wegovy? Both are once-weekly injections. Trulicity uses a single-button auto-injector pen with a hidden needle. Wegovy uses a prefilled pen with a visible needle that requires manual insertion. Injection sites are the abdomen, thigh, or upper arm for both medications.

What happens if I stop taking Trulicity or Wegovy? Weight regain is common after stopping either medication. In the STEP 1 trial extension, patients who stopped Wegovy regained approximately two-thirds of lost weight within 12 months. A1C rises back toward baseline within 8 to 12 weeks of stopping Trulicity. Both medications require ongoing use to maintain benefits.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Frias JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Lancet. 2021.
3. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
4. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
5. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
10. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Type 2 Diabetes. Diabetes Therapy. 2019.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
12. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
13. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
14. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.